Contextualizing Potential Risks of Medications in Pregnancy for the Newborn-the Case of Ondansetron

JAMA Pediatr. 2020 Aug 1;174(8):747-748. doi: 10.1001/jamapediatrics.2020.1325.

Authors

Krista F Huybrechts¹, Sonia Hernández-Díaz², Brian T Bateman^{1

3}

Affiliations

¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
³ Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

PMID: 32478805
DOI: 10.1001/jamapediatrics.2020.1325

No abstract available

Publication types

Review

MeSH terms

Antiemetics / adverse effects
Antiemetics / therapeutic use
Female
Humans
Infant, Newborn
Maternal Exposure / adverse effects*
Ondansetron / adverse effects
Ondansetron / therapeutic use*
Pregnancy
Pregnancy Complications / drug therapy*
Pregnancy Trimester, First
Vomiting / drug therapy*

Substances

Antiemetics
Ondansetron